WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a company spearheading the movement to restore hearing by harnessing the regenerative potential of progenitor cells in the body, today announced that David Lucchino, the Company’s Co-founder, President and Chief Executive Officer, will provide a corporate update at the Cowen & Company 37th Annual Healthcare Conference. The presentation will take place on Wednesday, March 8 at 2:30 p.m. The conference is being held from March 6 to 8 in Boston, MA.
“Frequency is poised to become an industry leader in regenerative medicine addressing chronic noise induced hearing loss,” said Mr. Lucchino. “With the recent publication in Cell Reports of a study by our co-founders validating the Frequency Progenitor Cell Activation Platform, we are rapidly advancing toward in-human trials targeting cellular regeneration within the inner ear to restore healthy tissue and reverse hearing loss. We expect to be in the clinic within the next 18 months. We are looking forward to presenting at the Cowen & Company Healthcare Conference to educate new audiences about the Frequency story and platform.”
ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. www.frequencytx.com.